Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 12 13 14 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cutiss–Univ Zurich: investment, 2017 seed funding from UZH Life Sciences Fund 2017-01-01
dKK GmbH–Bavaria (govt): science/business park services, 201704– supply serivce dKK GmbH Martinried is new tenant at IZB Martinsried 2017-01-01
Horizon Discovery–ERS Genomics: CRISPR technology, 201701– license ww non-excl expansion 2017-01-01
Immunic–Bavaria (govt): science/business park services, 201701– supply service Immunic AG is new tenant at IZB Martinsried 2017-01-01
Middle Peak Medical–Symetis: investment, before 2017 acquisition by Symetis SA 2017-01-01
Pionyr Immunotherapeutics–Minapharm: biopharma production, 2017– supply service cell line + process dev + production of therap antibody by ProBioGen 2017-01-01
Ridgeway Biologicals–Klocke: investment, 201701 acquisition of Ridgeway Biologicals by IDT Biologika 2017-01-01
SciMab–Bavaria (govt): science/business park services, 201701– supply serivce SciMab GmbH is new tenant at IZB Martinsried 2017-01-01
Genkyotex–Genticel: investment, 201612–201702 reverse merger with Genkyotex’ owners holding 80% of merged entity 2016-12-22
PerkinElmer–Varex Imaging: investment, 201612–201705 acquisition $276m cash of PE’s medical imaging business by Varex Imaging (Varian Medical Systems) 2016-12-22
C.B.S. Scientific–Genetrix (ES): investment, 201612 acquisition $900k of C.B.S. Scientific Company for $540k cash + $360k in shares by Sygnis AG 2016-12-21
Laagrima (MA)–SGS: investment, 201612 acquisition by SGS 2016-12-21
Purdue Pharma–Celltrion: rituximab, 201612– acquisition distribution rights for UK+IE+DE+IT+Benelux for biosimilar Truxima by Mundipharma 2016-12-20
C-Labs (CH)–SGS: investment, 201612 acquisition of controlling stake by SGS 2016-12-19
Active Spectrum–Bruker Corp: investment, 201612 acquisition €na of Active Spectrum by Bruker 2016-12-16
Ziarco–Novartis: investment, 201612 acquisition €na by Novartis ANNOUNCED 2016-12-16
Bluebird Bio–Apceth: contract manufacturing, 201612– collab strategic European manufacturing of Lenti-D + LentiGlobin by Apceth Biopharma GmbH 2016-12-15
Kohlberg Kravis Roberts–Lonza: investment, 201612–201707 acquisition of Capsugel for $5.5b in cash from KKR by Lonza 2016-12-15
Noxxon–Merck (US): cancer immunotherapy, 201612– collab clinical research combi of Keytruda + NOX-A12 in metastatic colorectal + pancreatic cancer 2016-12-15
Univercells–Gates Foundation: grant, 201612 grant $12m to reduce costs of vaccines for developing countries in collab w Batavia + Natrix 2016-12-15
Acousia Therapeutics–SEVERAL: investment, 201612 financing round €2.5m led by BIVF + incl KfW + Axxam 2016-12-14
Amcure–SEVERAL: investment, 201612 financing round Series B €6m led by LBBW Venture Capital GmbH 2016-12-14
Gilupi–Viroad: investment, 201612 acquisition of remaining shares in Gilupi by Viroad after becoming largest shareholder in 2012 2016-12-14
Carpegen–Lifescience Business Consulting: business consulting, 201612 supply portfolio/market analysis for sale of Gyronimo RT-PCR platform to Curetis 2016-12-13
Carpegen–Osborne Clarke: legal services, 201612 supply legal advisor for sale of Carpegen’s Gyronimo RT-PCR platform to Curetis 2016-12-13
Carpegen–Systec Elektronik: real-time PCR technology, 201612 collab existent development of Gyronimo platform co-owned by Carpegen + Systec 2016-12-13
Curetis–Carpegen: real-time PCR technology, 201612 acquisition €5m cash + €2.5m+€9m milestones of Gyronimo platform from Carpegen + Systec 2016-12-13
Genome Diagnostics–Illumina: DNA sequencing, 201612– collab GenDx non-excl reseller of Illumina porudcts for HLA sequencing in several countries 2016-12-13
BlueRock Therapeutics–Bayer: investment, 201612– financing round Series A totalling of $225m committed by Bayer + Versant Ventures 2016-12-12
BlueRock Therapeutics–SEVERAL: investment, 201612– launches with financing round Series A $225m committed by Bayer + Versant Ventures 2016-12-12
BlueRock Therapeutics–Versant Ventures: investment, 201612– financing round Series A totalling of $225m committed by Bayer + Versant Ventures 2016-12-12
Curetis–EU (govt): credit, 201612– up to €25m (incl €10m immediately) growth capital loan from EBI to advance Unyvery platform 2016-12-12
EURE-CART project–EU (govt): grant, 201612c– Horizon 2020 grant €5.9m 4y for clinical research on CART T-cell immunotherapy 2016-12-12
MolMed–EU (govt): grant, 201612c– Horizon 2020 grant €2m for MolMed for 4y as coordinator of EURE-CART project 2016-12-12
Biopremier (PT)–SGS: investment, 201612 acquisition of 70% stake by SGS 2016-12-09
Forge Therapeutics–Evotec: drug discovery services, 201612– collab strategic alliance lead optimisation of LpxC inhibitors by Evotec 2016-12-09
Numares–Ruth Group: public relations, 201612 service existent US PR + IR by The Ruth Group 2016-12-08
TCR2 Therapeutics–F2 Ventures: investment, 201612 financing round Series A totalling $44.5m led by MPM Capital + F2 Ventures 2016-12-07
TCR2 Therapeutics–MPM Capital: investment, 201612 financing round Series A totalling $44.5m led by MPM Capital + F2 Ventures 2016-12-07
TCR2 Therapeutics–SEVERAL: investment, 201612 financing round Series A $44.5m led by MPM Capital + F2 Ventures 2016-12-07
Roche–Novimmune: therapeutic antibody, 201612– excl license option €na for all rights to NI-0101 for autoimmune diseases to Genentech 2016-12-06
Acticor Biotech–Merck (DE): rec protein production, 201612– supply Provantage End-to-End Services for developm + manufacturing of Fab 2016-12-05
Bayer–FaunaPhotonics: digital farming technology, 201612– collab developm sensor technology for insect pest monitoring w Bayer CropScience 2016-12-05
JnJ–AstraZeneca: budenoside, 201612 acquisition $330m of ww rights excl US to Rhinocort Aqua by Cilag GmbH International 2016-12-05
International Phenome Centre Network–Bruker Corp: NMR technology, 201611– collab Bruker is key partner for NMR technologies + methods + SOPs 2016-12-02
International Phenome Centre Network–Imperial College London: phenomics, 201611– collab MRC-NIHR UK Phenome Centre is founding partner of IPCN 2016-12-02
International Phenome Centre Network–Murdoch Univ: phenomics, 201611– collab Separation Science + Metabolomics Lab is founding partner of IPCN 2016-12-02
Boehringer–Bruker Corp: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System in Biberach 2016-12-01
Celgene–Evotec: drug discovery services, 201612–202111 strategic RnD collab $45m upfront using iPSC platform for drugs neurodegenerative diseases 2016-12-01
Medigene–Coulter Partners: recruitment services, 201612 supply service placement of Thomas Taapken as new CFO of Medigene 2016-12-01
Roche–Bruker Corp: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System to Genentech 2016-12-01
Valneva–France (govt): investment, 201612 existent Bpifrance is 2nd largest shareholder owning 9.6% 2016-12-01
Valneva–Grimaud: investment, 201612 existent Groupe Grimaud is largest shareholder owning 15.6% 2016-12-01
Valneva–MVM: investment, 201612 private placement €7.5m w 2.9m new shares at €2.6 to MVM plus acqu existing shares results in 7.5% MVM share 2016-12-01
Boehringer–ACD/Labs: cheminformatics, 201611– supply deployment of ACD/Spectrus platform by Boehringer in Europe + North America 2016-11-30
Evotec–Merck (DE): target discovery technology, 201611– collab agreements to combine Merck genome editing technologies w Evotec screening (LT) 2016-11-30
G7 Therapeutics–Sosei: investment, 201611– acquisition 100% for CHF12m in cash of G7 Therapeutics by Heptares 2016-11-30
Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy 2016-11-30
AudioCure Pharma–High-Tech Gründerfonds: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors 2016-11-29
AudioCure Pharma–MED-EL: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors 2016-11-29
AudioCure Pharma–SEVERAL: investment, 201611 financing round €9m from new investor MED-EL + existing investor HTGF + private investors 2016-11-29
GeneWerk–GenoSafe: gene/cell therapy services, 201611– collab framwork agreem to offer combined research services 2016-11-29
Jackson Laboratory–Agilent: grant, 201611– Thought Leader Award to Peter Robinson at Jackons Lab for Genomic Medicine for clinical genomics research 2016-11-28
Menarini–Chugai: cancer drug, 201611– license ww excl for class I PI3K inhibitor PA799 to Berlin-Chemie Menarini 2016-11-28
Themis Bioscience–SEVERAL: investment, 201611 financing round Series B €10m 2nd + final closing with additional €3m 2016-11-28
Merck (US)–Proteros: drug discovery services, 201611– collab €na upfront + research funding + $167m milestones + royalties r+d small mol cancer drug 2016-11-22
Horizon Discovery–Sophia Genetics: genomic cancer testing, 201611– collab €na integrating HDx Reference Standards w DDM Platform for NGS cancer tests 2016-11-17
Epigenomics–Cathay Fortune: investment, 201611 private placement €2.1m w 474.8k new shares at €4.52/share fully subscribed by Cathay Fortune 2016-11-16
HTG–Qiagen: investment, 201611 minority investment by Qiagen North American Holdings as part of CDx collaboration 2016-11-16
Qiagen–HTG: molecular companion diagnostics, 201611– collab developm complete NGS solution from biomarker to CDx test 2016-11-16
Thar Pharmaceuticals–Grünenthal: investment, 201611 acquisition of Thar by Grünenthal 2016-11-16
UroMems–SEVERAL: investment, 201611 financing round Series A €12m led by Wellington Partners 2016-11-16
MorphoSys–BVF Partners: investment, 201611 private placement totalling €115m incl €52.8m from BVF Partners acquiring 1.2m shares at €44/share 2016-11-15
MorphoSys–SEVERAL: investment, 201611 private placement €115m w 2.622m new shares at €44/share to European + North American institutional investors 2016-11-15
OSE Immunotherapeutics–Selexis: cell line development, 201611– supply service access to research cell banks from SUREtechnology platform 2016-11-15
Roche–SEVERAL: cancer immunotherapy, 201611– establishment of imCORE Network by Roche with 21 ww academic centers 2016-11-15
Evotec–Univ Oxford: drug discovery, 201611– collab partnership LAB282 for early-stage projects out of Oxford Univ with OUI + OSI 2016-11-10
Kaye Scholer–Arnold & Porter: investment, 201611–201701 merger into Arnold & Porter Kaye Scholer LLP 2016-11-10
Qiagen–Genohm: LIMS, –201610– collab developm GeneRead Link middleware to connect GeneReader NGS data with LIMS 2016-11-09
CureVac–SEVERAL: investment, 201611 financing $29.5m led by new investors LBBW Asset (for BWVÄZT) + Landeskreditbank BW 2016-11-08
Epigenomics–SEVERAL: investment, 201611 private placement €5m 1.035m new shares at €4.83/share to UChip Technology Ltd + BioChain (BVI) Inc 2016-11-07
Takeda–AstraZeneca: digital pathology, 201611– collab using Definiens' newly launched VeriTrova cloud-based solution 2016-11-07
Aimmune Therapeutics–Nestlé: investment, 201611 equity investment $145m w 7.6m shares at $19.2/share by Nestlé Health Science 2016-11-04
Nestlé–Aimmune Therapeutics: immunotherapy, 201611– strategic collab to develop + commercialise food allergy therapies w Neslé Health Science 2016-11-04
Actelion–Reveragen: vamorolone, 201611– excl license option for Actelion 2016-11-03
AMP-Therapeutics–EnBiotix: investment, 201611 acquisition of AMPT via asset acquisition by newly established EnBiotix GmbH 2016-11-03
Merck (DE)–BioMed X: pharma research, 201611– collab Merck expansion funding new cancer research groups at BioMed X 2016-11-03
NBE Therapeutics–Boehringer: investment, 201611 financing round Series B CHF20m led by PPF Group wih BIVF + private investors 2016-11-03
NBE Therapeutics–SEVERAL: investment, 201611 financing round Series B CHF20m led by PPF Group wih BIVF + private investors 2016-11-03
Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies 2016-11-03
Bruker Corp–OTHER: nucleic acid diagnostics, 201611 acquisition €na of NAT assays + PCR techn assets in Glasgow for MALDI Biotyper platform 2016-11-02
Leo Pharma–MorphoSys: therapeutic antibodies, 201611– collab strategic alliance to develop ABs in dermatology using Ylanthia technology 2016-11-02
Calibration Technology (IE)–Eppendorf: investment, 201611 acquisition of CTL by Eppendorf 2016-11-01
Q Laboratories–Bruker Corp: mass spectrometer, 201611 supply MALDI Biotyper 2016-11-01
Sotax–Waters: liquid chromatography, 201611– distribution rights for Acquity UPLC H-Class Sytem for pharma labs in several countries for Sotax 2016-11-01
Ganymed–Astellas: investment, 201610– acquisition 100% of Ganymed for €422m upfront + €860m milestones by Astellas Pharma Inc 2016-10-28
Ganymed–Freshfields: legal services, 201610 advisor for Ganymed owners for sale of Ganymed to Astellas 2016-10-28
Mologen–Freshfields: legal services, 201610 advisor for capital increase + convertible bond issue 2016-10-28
BoneSupport–SEVERAL: investment, 201610 raised $47m (SEK327m) in combination of equity + debt finance 2016-10-27
Evolva–ERS Genomics: CRISPR technology, 201610– license ww non-excl €na to CRISPR technology for industrial applications 2016-10-27
next pagenext page 1 2 3 ... 12 13 14 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top